XML 47 R32.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information
The following table presents selected financial information with respect to the Company’s single operating segment for each period presented:
Three Months Ended March 31,
20262025
Collaboration revenue$875 $20,558 
Less:
Research and development expenses
Direct research and development expenses
ENTR-601-444,755 4,734 
ENTR-601-453,602 2,859 
ENTR-601-501,369 692 
ENTR-601-512,337 826 
DMD franchise-wide(1)
1,739 — 
Collaboration services234 876 
Ocular programs
461 270 
Other preclinical and discovery599 987 
Unallocated research and development expenses
Personnel related (including stock-based compensation)12,041 12,756 
Facility related and other5,917 8,074 
Total research and development expenses33,054 32,074 
General and administrative expenses10,124 10,274 
Interest and other income2,624 4,441 
Provision for (benefit from) income taxes
38 — 
Net (loss) income
$(39,717)$(17,349)
(1)Represents manufacturing and clinical costs that support across the Company's product candidates targeting DMD.